PixCell takes five-minute HemoScreen blood testing into Canada through Inter Medico

PixCell Medical has entered the Canadian diagnostics market after receiving a Health Canada Class III Medical Device Licence for HemoScreen, its portable point-of-care hematology analyzer, and appointing Inter Medico as its local distribution partner. HemoScreen can generate a complete blood count with five-part white-cell differential from venous or capillary blood in approximately five minutes, using a disposable cartridge that contains the sample and required reagents without exposing the analyzer itself to blood or liquid chemicals. The system combines AI-assisted digital imaging with PixCell Medical’s proprietary Viscoelastic Focusing technology and does not require routine calibration, external liquid reagents or the maintenance associated with many conventional hematology analyzers. Canada creates an unusually logical expansion market because geographic dispersion and rural healthcare access increase the potential value of obtaining laboratory-grade hematology results closer to patients rather than transporting samples to centralized laboratories.

The distribution agreement also gives privately held PixCell Medical local infrastructure it would have been expensive to build independently. Inter Medico has spent more than 45 years distributing diagnostic technologies across Canada and provides training, service and bilingual customer support, while its portfolio already spans hematology, molecular diagnostics, pathology, microbiology and other laboratory categories. PixCell can therefore concentrate on manufacturing and product development while using an established diagnostics organization to reach hospitals, community clinics, oncology centers and remote healthcare sites.

What does HemoScreen actually provide from a single point-of-care blood sample?

HemoScreen measures 20 standard complete blood count parameters and provides a five-part leukocyte differential, covering measurements that are routinely used to assess anemia, infection, immune status, platelet abnormalities and other common clinical conditions. PixCell says results are available in about five minutes after blood is collected and loaded into its single-use lab-on-cartridge system. The analyzer is portable and requires no routine calibration or liquid reagent handling, reducing operational requirements compared with larger central-laboratory hematology instruments.

The underlying technology uses microfluidics and Viscoelastic Focusing to align cells as they move through the cartridge, allowing digital imaging algorithms to identify and classify them. Blood and reagents remain sealed inside the disposable cartridge throughout processing, which helps simplify cleaning and biosafety requirements because liquids do not enter the analyzer’s internal components. The approach effectively shifts complexity away from the operator and into the consumable cartridge, imaging system and software.

That design has commercial implications because point-of-care technologies often fail when they require laboratory-level technical skill despite being deployed outside laboratories. HemoScreen still has to be operated according to relevant local training and quality requirements, but reducing manual reagent handling and calibration makes the system more practical for sites where specialist hematology technicians are unavailable.

Why could Canada be a particularly useful market for decentralized CBC testing?

Nearly one in five Canadians lives in a rural area, while healthcare facilities can be separated from centralized laboratories by significant distances. In those settings, routine blood samples may need transportation before testing, creating delays between collection and treatment decisions. PixCell and Inter Medico are positioning HemoScreen as an option for hospitals, clinics and remote facilities that need rapid hematology information without maintaining a full central-laboratory setup.

The value becomes more obvious in clinical situations where a complete blood count influences an immediate decision. Oncology centers, for example, frequently require blood counts before determining whether a patient can safely receive chemotherapy, while emergency departments may need white-cell, hemoglobin and platelet information quickly when assessing infection, bleeding or anemia. PixCell specifically markets HemoScreen for oncology workflows where reducing turnaround time can determine whether treatment proceeds during the same visit.

Point-of-care testing does not remove the need for central laboratories because complex morphology, unusual flags and confirmatory testing still require specialist review. PixCell’s own U.S. operating guidance indicates that certain abnormal flags require further laboratory verification. The commercial proposition is therefore not replacing every hematology analyzer but moving routine CBC testing closer to the patient where turnaround time has enough clinical value.

How does Canadian authorization build on HemoScreen’s existing regulatory history?

HemoScreen is not entering Canada as an entirely untested device. The U.S. FDA originally cleared the hematology analyzer through the 510(k) pathway in 2018, and PixCell has subsequently obtained additional U.S. clearances associated with the platform. FDA records classify HemoScreen as an automated differential cell counter under hematology regulation 21 CFR 864.5220.

The company also holds CE marking and other international certifications, while its recent Medical Device Single Audit Program certification supported Canadian market access. The new Class III licence therefore expands an existing regulatory footprint rather than representing the device’s first commercial authorization. That distinction can matter for Canadian providers because previous clinical and operational use gives hospitals more evidence to evaluate than would be available for a completely new analyzer.

The regulatory record also shows that HemoScreen has evolved over time. Subsequent FDA submissions have modified or extended the cleared system, demonstrating a continued product-development cycle rather than reliance solely on the original 2018 configuration.

Why is Inter Medico more important than simply having a Canadian distributor?

Medical diagnostics sales depend heavily on technical service after placement. A hospital buying a hematology analyzer expects installation support, training, troubleshooting, consumable availability and rapid response when a system is unavailable. Those requirements make local infrastructure especially important for a privately held manufacturer entering a large country where customers may be geographically dispersed.

Inter Medico already supports diagnostics across multiple laboratory disciplines and provides 24-hour bilingual customer service. Its established relationships give PixCell a route into laboratories and healthcare systems without recreating a Canadian sales and technical-support organization from the ground up.

The partnership also reduces one of the hidden barriers facing smaller medtech companies after regulatory authorization. A licence creates legal market access, but it does not automatically produce hospital purchasing, training or service capability. Using an established distributor can compress the gap between authorization and actual clinical adoption, although commercial terms between PixCell and Inter Medico were not disclosed.

Could HemoScreen build a recurring-revenue model through disposable cartridges?

The analyzer uses a single-use cartridge and sampler for each complete blood count, creating a classic instrument-plus-consumables business model. A system placement can therefore produce recurring revenue whenever the healthcare provider performs another test, making utilization potentially more important over time than the number of analyzers installed. U.S. product information shows that each disposable unit contains the blood sample and reagents required for one CBC measurement.

That model can be attractive when test volume is high because every active instrument creates continued cartridge demand. The commercial challenge is ensuring that smaller rural sites perform enough tests to justify placing and supporting the analyzer while still benefiting from decentralized access. Larger oncology centers, emergency facilities and community hospitals may provide higher volume, while remote sites could offer stronger clinical value but lower consumable throughput.

PixCell has not disclosed revenue, Canadian pricing, expected instrument placements or the economics of its Inter Medico agreement, so the immediate financial impact cannot be quantified. The strategic significance lies instead in opening another developed healthcare market using a distribution model that could be repeated geographically.

HemoScreen does not need to replace central hematology laboratories to build a viable business. Its opportunity sits in the gap between sending every routine blood sample away for testing and purchasing a conventional full-scale analyzer for locations that cannot support one. Canada will now test whether five-minute CBC testing from a portable cartridge system can turn that gap into meaningful clinical adoption.